ADP-A2M4CD8 T-Cell Therapy for Esophageal Cancer

Recruiting in Palo Alto (17 mi)

+43 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Adaptimmune

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

Research Team

Eligibility Criteria

This trial is for adults aged 18-75 with esophageal or esophagogastric junction cancers that express MAGE-A4 and are HLA-A*02 positive. Participants must have had prior treatment, measurable disease, good performance status (ECOG 0 or1), and a heart ejection fraction of at least 50%. Exclusions include uncontrolled illness, pregnancy, certain cardiovascular diseases, previous allergic reactions to study drugs, other active malignancies not in remission, CNS metastases, and active infections.

Inclusion Criteria

You have already received treatment for advanced or spreading disease.

HLA-A*02 positive

Tumor shows MAGE-A4 expression confirmed by central laboratory.

See 6 more

Exclusion Criteria

You have a serious medical condition that is not well-managed.

Positive for any HLA-A*02 allele other than: one of the inclusion alleles

You are pregnant or currently breastfeeding.

See 6 more

Treatment Details

Interventions

ADP-A2M4CD8 (CAR T-cell Therapy)

Trial OverviewThe trial tests ADP-A2M4CD8 T-cell therapy in patients with specific genetic markers whose cancer cells express the MAGE-A4 protein. It aims to evaluate the effectiveness of these genetically modified cells in targeting and fighting cancer.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Autologous genetically modified ADP-A2M4CD8 cellsExperimental Treatment1 Intervention